论文部分内容阅读
多核铂配合物作为非经典铂抗肿瘤药物,其抗肿瘤机制与现有铂类抗肿瘤药物不同,因而在克服现有铂类抗肿瘤药物耐药性方面有着巨大的潜力。本文综述了多核铂类抗肿瘤药物的研究进展,以连接铂原子的桥配体结构的不同,可分为六大类:以烷基二胺及其衍生物为桥的多核铂配合物、以含氮杂环为桥的多核铂配合物、以羧酸根为桥的多核铂配合物、以卤素离子为桥的多核铂配合物、以含硫配体为桥的多核铂配合物及以其他配体为桥的多核铂配合物。本文还介绍了这几类多核铂配合物的抗肿瘤机理及在克服顺铂耐药性机理方面的研究进展。
Polynuclear platinum complexes, as non-classical platinum anticancer drugs, have different antitumor mechanisms than the existing platinum anticancer drugs and therefore have great potential to overcome the existing drug resistance of platinum antitumor drugs. This review summarizes the progress of research on antitumor drugs of multi-nuclear platinum. The structure of bridged ligands connecting platinum atoms can be divided into six categories: polynuclear platinum complexes bridged by alkyl diamines and their derivatives, Polynuclear platinum complexes containing a nitrogen-containing heterocycle as a bridge, polynuclear platinum complexes based on carboxylate bridges, polynuclear platinum complexes containing a halide as a bridge, polynuclear platinum complexes containing a sulfur-containing ligand as a bridge, The body is a bridge of polynuclear platinum complexes. This article also introduced the antitumor mechanism of these types of polynuclear platinum complexes and the research progress in overcoming the cisplatin resistance mechanism.